Biogen’s Alzheimer’s drug is unlikely to win E.U. approval. The drug, Aduhelm, has been mired in controversy since it [...] By digitalstudios|2021-11-18T04:32:41+00:00November 18, 2021|3rd Party Pharmaceutical Industry News|Comments Off on Biogen’s Alzheimer’s drug is unlikely to win E.U. approval. Read More